Clinical trials: Hpv
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Condylomata Acuminata
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
This study was conducted to demonstrate that Gardasil™ (quadrivalent human papillomavirus [qHPV] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence…
- Trial name
- NCT00090285
- Testing
- (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV16 Anitbody Levels Post Vaccination, HPV18 Antibody Levels Post Vaccination
HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda
Background: Cervical cancer is one of the leading causes of cancer death in women worldwide and in Uganda. It is caused by the human papillomavirus (HPV).
- Trial name
- NCT01520272
- Where
- Uganda
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HPV Infection, HPV Vaccination
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection.
- Trial name
- NCT05435209
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- Kenya
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- University of Washington
HPV 16 Infection
Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.
- Trial name
- NCT00365378
- Testing
- Comparator: HPV 16 L1 Vaccine
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections, Genital Diseases, Female
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
This study was conducted in 2 parts. Part A was a randomized, double-blind, placebo-controlled, multicenter, sequential dose-escalating evaluation.
- Trial name
- NCT00365716
- Testing
- Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
- Volunteers
- 1,158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Patient Compliance
Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study
There has been very limited research that has looked at electronic reminders (text messages) and its effectiveness in adherence to vaccination among low-income minority populations.
- Trial name
- NCT01908517
- Testing
- HPV Vaccine Electronic Reminders
- Where
- 2 sites in United States
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- East Carolina University
School Health Services
Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers
School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness.
- Trial name
- PEER (NCT07412743)
- Testing
- Mailers, Provider Materials, Peer-to-Peer Educational Sessions
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Kaiser Permanente
Infections, Papillomavirus
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
- Trial name
- NCT01153906
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities
The goal of this observational study is to assess the five-year incidence of histologically confirmed cervical cancer among women who test positive for human papillomavirus (HPV) with low-grade cytological abnormalities, to…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
- Trial name
- NCT07259616
- Volunteers
- 46,079 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Menstrual Disorder, Premature Ovarian Failure
The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
Cervical cancer is one of the most common cancer in women, making it the fourth largest cause of female cancer mortality worldwide.
- Trial name
- NCT05838157
- Testing
- prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Human Papilloma Virus (HPV), Cervical Carcinoma
Transmission of Oncogenic HPV Infection Among Families
The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families.
- Conditions
- Human Papilloma Virus (HPV), Cervical Carcinoma, Oropharyngeal Carcinoma, Transmission Vertical
- Trial name
- TREVINO (NCT07036211)
- Where
- 2 sites in Finland
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Human Papilloma Virus
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
flat warts are a superficial viral skin disease, extremely common in childhood.Treatment of warts is often difficult and involves different destructive procedures.Although several pharmacological and physical topical treatments…
- Trial name
- NCT05146895
- Testing
- Imiquimod treatment, Local Hyperthermia at 44℃
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- First Hospital of China Medical University
HIV, Chlamydia
National Rapid TLC: Testing and Linkage to Care
The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics.
- Conditions
- HIV, Chlamydia, Gonorrhea, HCV
- Trial name
- NCT07730801
- Testing
- Xpert® HIV-1 Qual XC
- Where
- 2 sites in Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Immunization, Vaccination
The STOP-HPV Trial 2: Performance Feedback Intervention
Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates.
- Trial name
- STOP-HPV (NCT03599570)
- Testing
- STOP-HPV performance feedback intervention
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HPV VACCINATION
Health Belief Model-based Education and Motivational Interview Regarding the HPV Vaccination Decision
This research is a single-blind, randomized, parallel-controlled experimental study designed to determine the effect of Health Belief Model (SIM)-based motivational interviews given to mothers of high school students on mothers'…
- Trial name
- NCT04992741
- Testing
- education and motivational interview
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Yasemin ATEŞEYAN
Warts, Human Papilloma Virus
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
- Trial name
- NCT05291845
- Testing
- Candida antigen vaccine, Bivalent HPV vaccine
- Where
- Egypt
- Volunteers
- 162 people
- Sponsor
- Zagazig University
Cervical Cancer
Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer
- Trial name
- NCT05539274
- Testing
- human papilloma virus testing and genotyping in cervical cancer cases
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Hossam Hassan Aly Hassan El Sokkary
Uterine Cervical Cancer
Evaluation of Long-term HPV Vaccine Efficacy
Summary For ethical and practical reasons pre-licensure clinical efficacy phase III trials for GSK Biologicals' HPV-16/18 LI VLP AS04 vaccine used cervical intraepithelial grade 2 and above (CIN2+) lesions as surrogate efficacy…
- Trial name
- NCT01393470
- Testing
- Screening for cervical cancer
- Where
- 15 sites in Finland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Tampere University
Papilloma Virus, Human
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists.
- Trial name
- HPV (NCT01206556)
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group